Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib added to alfuzosin for trial without catheter after first acute urinary retention episode due to benign prostatic hyperplasia
ACTRN12614000202662Phase 3Withdrawn
- Sponsor
- Gennimatas General Hospital of Thessaloniki
- Start
- Apr 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute urinary retention and benign prostatic hyperplasia (BPH) comparing Alfuzosin + celecoxib with Alfuzosin + placebo (2 arms). Primary endpoint: Successful trial without catheter. Planned start Apr 2014; status: withdrawn.
02
Drugs
celecoxibalfuzosin
03
Conditions
acute urinary retentionbenign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on ACTRN12614000202662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000202662.